EyePoint, Inc. EYPT
0.33 USD -0.03 (-8.75%)
Nov 12, 2026, 2:21 PM EST
0.31 Day range 0.3618
0.31 52-week range 19.11
- YTD
- -98.22%
- 1 year
- -97.29%
News
seekingalpha.com EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
zacks.com EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates EyePoint (EYPT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.85 per share a year ago.
benzinga.com EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript EyePoint Pharmaceuticals (NASDAQ:EYPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com EyePoint Pharmaceuticals Q3 EPS $(1.07) Misses $(0.91) Estimate, Sales $756.000K Beat $223.077K Estimate EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.91) by 17.58 percent. This is a 25.88 percent decrease over…
globenewswire.com EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
globenewswire.com EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
globenewswire.com EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026 WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with…
benzinga.com RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1 RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Sector Perform and lowers the price target from $5 to $1.
benzinga.com Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
benzinga.com Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39.…
benzinga.com EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
benzinga.com Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
benzinga.com Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint – LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –– Key secondary…
benzinga.com Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
benzinga.com This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
benzinga.com TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4 TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the price target from $20 to $4.
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
benzinga.com These Analysts Slash Their Forecasts On EyePoint EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.- benzinga.com Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17 Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $35 to $17.
benzinga.com RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5 RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
benzinga.com Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5 Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
benzinga.com Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,459.78
benzinga.com Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release,…- benzinga.com Jefferies Maintains Buy on EyePoint, Lowers Price Target to $8 Jefferies analyst Kambiz Yazdi maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $8.
benzinga.com Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
benzinga.com EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden despite primary endpoint challenges.
benzinga.com Dow Falls 150 Points; NY Empire State Manufacturing Index Rises In August US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech shares up 0.4%, consumer staples down 0.8%.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…- benzinga.com EyePoint Reports DURAVYU Non‑Inferior To Aflibercept In Ad Hoc Analysis; Primary BCVA Endpoint Not Met In Full Dataset EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced topline…
- benzinga.com EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15…
benzinga.com Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Thursday Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed EyePoint's target, Goldman cut Sunrun's, B of A lowered Coupang's, BTIG cut Klaviyo's, Jefferies…- benzinga.com Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55 Cantor Fitzgerald analyst Steve Seedhouse maintains EyePoint (NASDAQ:EYPT) with a Overweight and raises the price target from $47 to $55.
benzinga.com HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27 HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $27.
benzinga.com EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over…
benzinga.com This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Wall Street analysts change outlook on top names. Check out analyst ratings page for upgrades, downgrades, and initiations. See how analysts view RMBS.
benzinga.com Stifel Initiates Coverage On EyePoint with Buy Rating, Announces Price Target of $40 Stifel analyst Annabel Samimy initiates coverage on EyePoint (NASDAQ:EYPT) with a Buy rating and announces Price Target of $40.
benzinga.com 6 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Cantor Fitzgerald Assumes EyePoint at Overweight, Announces Price Target of $47 Cantor Fitzgerald analyst Steve Seedhouse assumes EyePoint (NASDAQ:EYPT) with a Overweight rating and announces Price Target of $47.
- benzinga.com Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65 Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ:EYPT) with a Buy and raises the price target from $29 to $65.
- benzinga.com RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37 RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Outperform and lowers the price target from $39 to $37.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Marriott Vacations To Rally Around 52%? Here Are 10 Top Analyst Forecasts For Thursday Summary:Top Wall Street analysts changed outlook on top names. Analyst ratings page shows all changes. VEEV, GENI, DOW, BLLN, OKTA, VAC, WLK, EYPT had price target changes.- benzinga.com Earnings Scheduled For March 4, 2026
benzinga.com The Year-End 2025 Biotech Rally And What It Means For 2026